Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Bertrand Cariou

Showing results (11-20 of 311) with videos related to

Pageof 32
Sort By:
Expert Opinion on Investigational Drugs|August 29, 2014
GFT505 for the treatment of nonalcoholic steatohepatitis and type 2 diabetesBertrand Cariou, Bart Staels
La Revue Du Praticien|December 6, 2011
[Management of hypercholesterolemia: what target for LDL cholesterol?]Bertrand Cariou, Michel Krempf
Diabetes Research and Clinical Practice|October 1, 2015
mTOR inhibitors and diabetesBruno Vergès, Bertrand Cariou
Trends in Pharmacological Sciences|April 7, 2007
FXR: a promising target for the metabolic syndrome?Bertrand Cariou, Bart Staels
Journal of Hepatology|April 19, 2006
The expanding role of the bile acid receptor FXR in the small intestineBertrand Cariou, Bart Staels
The Journal of Clinical Endocrinology and Metabolism|May 19, 2025
Non-invasive tests developed using artificial intelligence for screening in MASLD: interest and pitfallsJerome Boursier, Bertrand Cariou
La Revue Du Praticien|December 5, 2018
[LDL-cholesterol hypothesis:the lower is trully better]Bertrand Cariou, Sarra Smati
Expert Opinion on Investigational Drugs|November 10, 2015
Sotagliflozin as a potential treatment for type 2 diabetes mellitusBertrand Cariou, Bernard Charbonnel
Medecine Sciences : M/S|April 24, 2010
[Cholesterol metabolism and beta-cell function]Cédric Langhi, Bertrand Cariou
Annales D'Endocrinologie|August 16, 2017
34<sup>e</sup> Congrès SFE Poitiers 2017Bertrand Cariou, Philippe Caron
Pageof 32

Showing results (11-20 of 311) with videos related to

Sort By:
Pageof 32
Expert Opinion on Investigational Drugs|August 29, 2014
GFT505 for the treatment of nonalcoholic steatohepatitis and type 2 diabetesBertrand Cariou, Bart Staels
La Revue Du Praticien|December 6, 2011
[Management of hypercholesterolemia: what target for LDL cholesterol?]Bertrand Cariou, Michel Krempf
Diabetes Research and Clinical Practice|October 1, 2015
mTOR inhibitors and diabetesBruno Vergès, Bertrand Cariou
Trends in Pharmacological Sciences|April 7, 2007
FXR: a promising target for the metabolic syndrome?Bertrand Cariou, Bart Staels
Journal of Hepatology|April 19, 2006
The expanding role of the bile acid receptor FXR in the small intestineBertrand Cariou, Bart Staels
The Journal of Clinical Endocrinology and Metabolism|May 19, 2025
Non-invasive tests developed using artificial intelligence for screening in MASLD: interest and pitfallsJerome Boursier, Bertrand Cariou
La Revue Du Praticien|December 5, 2018
[LDL-cholesterol hypothesis:the lower is trully better]Bertrand Cariou, Sarra Smati
Expert Opinion on Investigational Drugs|November 10, 2015
Sotagliflozin as a potential treatment for type 2 diabetes mellitusBertrand Cariou, Bernard Charbonnel
Medecine Sciences : M/S|April 24, 2010
[Cholesterol metabolism and beta-cell function]Cédric Langhi, Bertrand Cariou
Annales D'Endocrinologie|August 16, 2017
34<sup>e</sup> Congrès SFE Poitiers 2017Bertrand Cariou, Philippe Caron
Pageof 32